Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
Eledon Pharmaceuticals (ELDN) Stock Price & Analysis
742 Followers
ELDN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.07 - $3.35
Previous Close$2.7
Volume37.38K
Average Volume (3M)202.62K
Market Cap
$103.97M
Enterprise Value$61.39M
Total Cash (Recent Filing)$42.86M
Total Debt (Recent Filing)$284.00K
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Aug 08, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding38,506,614
10 Day Avg. Volume213,075
30 Day Avg. Volume202,622
Standard Deviation0.31
R-Squared0.02
Alpha-0.00777
Financial Highlights & Ratios
Price to Book (P/B)2.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$14.00Price Target Upside418.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Eledon Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical ProgressEledon Pharmaceuticals announced clinical progress with tegoprubart, the company’s novel anti-CD40L antibody, as an investigational treatment for prevention of organ transplant rejection.
Efficacy And TolerabilityAdditional data for tegoprubart in kidney transplantation continue to support best-in-class potential based on possible advantages in efficacy and safety/tolerability compared to current standard-of-care.
Safety ProfileTegoprubart continues to be generally safe and well-tolerated in the Phase Ib study with no cases of hyperglycemia, new onset diabetes, or tremor reported to date.
Bears Say
Clinical TrialsRisks to the investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, and unproven commercialization strategy.
Infection ReportsFive cases of BK viremia and two cases of cytomegaloviremia have been reported.
Patient SafetyThree subjects have discontinued treatment due to hair loss and fatigue, viral infection, and rejection.
---
Ownership Overview
72.17% Insiders
3.04% Mutual Funds
22.67% Other Institutional Investors
2.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $1.07 and its highest was $3.35 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Currently, no data Available
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 18 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.366 by $0.026.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -$0.3.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 38,506,615 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.366. Following the earnings report the stock price went down -1.639%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Among the largest hedge funds holding Eledon Pharmaceuticals’s share is Woodline Partners LP. It holds Eledon Pharmaceuticals’s shares valued at 1M.
---
Eledon Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (418.52% Upside)
$14.00 (418.52% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 37.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.08%
12-Months-Change
Fundamentals
Return on Equity
-53.27%
Trailing 12-Months
Asset Growth
-1.81%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory pathway to develop and commercialize precision therapies for persons undergoing organ and cellular transplantation, and for people living with autoimmune and neurodegenerative disease. The company’s lead compound in development is tegoprubart (AT-1501), an anti-CD40L antibody. The company, which was established in 2004, is headquartered in Irvine, CA.
---
ELDN Earnings Call
Q1 2023
0:00 / 0:00
---
ELDN Stock 12 Month Forecast
Average Price Target
$14.00
▲(418.52% Upside)
Technical Analysis
Best Analysts Covering ELDN
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
+10.21%
reiterated a buy rating 2 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +10.21% per trade.
---